Core Viewpoint - China Biologic Products (01177.HK) has received approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug, Rovaxitinib Tablets (brand name: Anxu®), for first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) [1] Group 1 - Rovaxitinib is a globally innovative small molecule inhibitor targeting both JAK and ROCK pathways, providing dual effects of anti-inflammation and anti-fibrosis [1] - The drug works by inhibiting the JAK1/2-STAT3/5 signaling pathway, reducing high levels of inflammatory cytokines produced by myeloid cells, thus improving splenomegaly and systemic symptoms [1] - Additionally, it suppresses ROCK1/2 to lower the polarization level of T helper cells and the burden of inflammatory cytokines in patients with myelofibrosis, further enhancing anti-inflammatory effects and supporting long-term disease control [1]

Core Viewpoint - China National Pharmaceutical Group's innovative drug, Rovaxitinib (brand name: Anxu), has received approval from the National Medical Products Administration (NMPA) for the treatment of intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) in adult patients as a first-line therapy [1] Group 1: Drug Efficacy - Rovaxitinib is a first-in-class JAK/ROCK dual-target small molecule inhibitor that provides dual effects of anti-inflammation and anti-fibrosis through the inhibition of the JAK1/2-STAT3/5 signaling pathway and ROCK1/2 [1] - In a Phase II clinical study (TQ05105-II-01) involving 107 patients, Rovaxitinib demonstrated superior efficacy compared to hydroxyurea, with 58.33% of patients achieving a spleen volume reduction of ≥35% (SVR35) at week 24 [2] - The average duration of SVR35 was reported to be 8.31 months, and the total symptom score improvement of ≥50% (TSS50) was achieved by 77.78% of patients [2] Group 2: Safety Profile - Rovaxitinib exhibited good overall tolerability, with a ≥ grade 3 adverse reaction rate of approximately 40% and an anemia occurrence rate of about 40% [2] - The treatment discontinuation rate was only 6.7%, significantly lower than that of ruxolitinib [2] Group 3: Future Development - Beyond myelofibrosis, Rovaxitinib shows promising potential in the treatment of chronic graft-versus-host disease (cGVHD), currently in Phase III clinical trials in China and has been included in the breakthrough therapy program by the NMPA [2] - In the United States, Rovaxitinib has been approved to initiate Phase II clinical research for cGVHD [2]

Core Viewpoint - China National Pharmaceutical Group's innovative drug, Rovaxitinib (brand name: Anxu®), has received approval from the National Medical Products Administration (NMPA) for the treatment of intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) in adult patients as a first-line therapy [1][2] Group 1: Drug Approval and Mechanism - Rovaxitinib is a globally first-in-class JAK/ROCK dual-target small molecule inhibitor that achieves dual efficacy through anti-inflammatory and anti-fibrotic effects [1] - The drug works by inhibiting the JAK1/2–STAT3/5 signaling pathway to reduce high levels of inflammatory cytokines produced by myeloid cells, improving splenomegaly and systemic symptoms [1] - Additionally, it inhibits ROCK1/2 to lower the polarization level of T helper cells and inflammatory cytokine load in patients with myelofibrosis, further enhancing anti-inflammatory effects [1] Group 2: Clinical Trial Results - In a Phase II clinical study (TQ05105-II-01), Rovaxitinib demonstrated superior efficacy and good safety compared to hydroxyurea in treating intermediate-2 and high-risk myelofibrosis patients [2] - The study included 107 patients, randomized in a 2:1 ratio to receive either Rovaxitinib 15mg or hydroxyurea 0.5g, administered orally twice daily [2] - Efficacy results showed that 58.33% of patients in the Rovaxitinib group achieved a ≥35% reduction in spleen volume (SVR35) at week 24, with an average duration of SVR35 lasting 8.31 months and a total symptom score improvement rate of 77.78% [2] - The overall tolerability of Rovaxitinib was good, with a ≥ grade 3 adverse reaction rate of approximately 40% and a treatment discontinuation rate of only 6.7%, significantly lower than that of ruxolitinib [2] Group 3: Future Development - Beyond myelofibrosis, Rovaxitinib shows breakthrough potential in treating chronic graft-versus-host disease (cGVHD) [2] - The product is currently in Phase III clinical trials for cGVHD in China and has been included in the breakthrough therapy program by the NMPA, with plans for a Phase II clinical study approved in the United States [2]